MedPath

Iopamidol

Generic Name
Iopamidol
Brand Names
Isovue 200, Isovue 250, Isovue 300, Isovue 370, Isovue-M, Isovue-M 200
Drug Type
Small Molecule
Chemical Formula
C17H22I3N3O8
CAS Number
60166-93-0
Unique Ingredient Identifier
JR13W81H44
Background

Iopamidol is a contrast agent developed by Bracco with nonionic, low-osmolar properties.

Indication

本品用于腰、胸肌颈段脊髓造影，脑血管造影，周围动脉造影剂静脉造影；也用于心血管、冠状动脉、尿路、关节等的造影剂CT增强。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT

Phase 4
Completed
Conditions
IV Contrast Dosing
Interventions
Drug: Isovue 370
Other: Weight calculation
First Posted Date
2014-06-23
Last Posted Date
2015-01-07
Lead Sponsor
Duke University
Target Recruit Count
139
Registration Number
NCT02170688

Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC)

Phase 4
Completed
Conditions
Gastrointestinal Complication
Interventions
Drug: Bisacodyl & PEG-CS
Drug: Iopamidol
First Posted Date
2014-01-20
Last Posted Date
2014-01-20
Lead Sponsor
Azienda Policlinico Umberto I
Target Recruit Count
52
Registration Number
NCT02040285
Locations
🇮🇹

Policlinico Umberto I, Roma, Italy

Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography

Phase 4
Completed
Conditions
Drug Safety
Interventions
Drug: Iopamidol
Drug: Iodixanol
First Posted Date
2011-11-21
Last Posted Date
2014-06-11
Lead Sponsor
GE Healthcare
Target Recruit Count
255
Registration Number
NCT01475097
Locations
🇺🇸

GE Healthcare, Princeton, New Jersey, United States

Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis

Phase 4
Completed
Conditions
Patient Comfort and Safety
Interventions
Drug: Iodixanol
Drug: Iopamidol
First Posted Date
2011-06-20
Last Posted Date
2013-12-19
Lead Sponsor
GE Healthcare
Target Recruit Count
304
Registration Number
NCT01376089
Locations
🇺🇸

GE Healthcare, Princeton, New Jersey, United States

Kidney Damage in Patients With Moderate Fall in eGFR

Phase 4
Completed
Conditions
Coronary Artery Stenosis
Interventions
Drug: Iodixanol-320
Drug: Iopamidol
First Posted Date
2010-06-04
Last Posted Date
2020-11-04
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
57
Registration Number
NCT01136876
Locations
🇺🇸

UMDNJ - RWJ Medical School, New Brunswick, New Jersey, United States

🇨🇦

Montreal Heart Institute, Montréal, Quebec, Canada

🇺🇸

The Institute for Clinical Research at Holy Name Medical Center, Teaneck, New Jersey, United States

and more 1 locations

Isovue in Peripheral Digital Subtraction Angiography (DSA)

Phase 4
Completed
Conditions
Peripheral Arterial Occlusive Disease
Interventions
Drug: iopamidol
Drug: iodixanol
First Posted Date
2010-02-25
Last Posted Date
2013-05-30
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
174
Registration Number
NCT01075217
Locations
🇺🇸

Bracco Diagnostics, Princeton, New Jersey, United States

Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA

Phase 4
Completed
Conditions
Peripheral Arterial Occlusive Disease
Interventions
Drug: VISIPAQUE 270
Drug: Isovue 250
First Posted Date
2008-08-22
Last Posted Date
2011-05-09
Lead Sponsor
Bracco Diagnostics, Inc
Target Recruit Count
33
Registration Number
NCT00740207
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy